How Often Can You Take Mounjaro — and What Happens If You Miss a Dose?

The myth that more doses means faster results, and why it's wrong

People searching for how often they can take Mounjaro sometimes arrive at that question hoping the answer is 'more than once a week if needed'. It isn't. The once-weekly schedule isn't a conservative default; it's built into the pharmacology. Tirzepatide has a half-life of around five days, meaning it stays active in your body across the full seven-day window between injections. Shortening that gap doesn't add therapeutic effect, it stacks the drug's concentration in a way that sharply raises the likelihood of nausea, vomiting and other gastrointestinal side effects.

The titration schedule exists for the same reason. Treatment starts at 2.5 mg not because that dose produces significant weight loss, but because it allows your digestive system to adapt before the dose rises. Your prescriber controls each step. Taking an extra injection, or moving to the next strength ahead of the clinical review, bypasses that safety mechanism entirely. The NHS guidance on tirzepatide is clear that dose changes should follow medical advice, not personal judgement.

If you're finding the current dose difficult to tolerate, the right conversation is with your prescriber, not a different dosing frequency, and understanding how you can get Mounjaro through a proper clinical pathway is the most straightforward place to start.

What 'once a week' actually looks like in practice

You pick a day at the start of treatment and try to stick to it. If Tuesday works (before breakfast, say) you aim for every Tuesday. The gap between injections should be at least five days if you ever need to shift the day slightly; your flexibility around the timing of a Mounjaro injection is modest rather than wide. The Mounjaro KwikPen arrives pre-filled: each pen holds four weekly doses, dial-and-inject, with no reconstitution needed. When the pen arrives from our pharmacy in its plain, unbranded DPD box, you'll have a tracking notification on your phone before it lands, the pen itself stores in the fridge at 2–8°C until you need it.

Injection sites rotate between the abdomen, thigh and upper arm. Staying with the same site repeatedly can affect absorption and cause local reactions. Alcohol swabs and a new needle each time are standard practice. For the exact storage window at room temperature, the Mounjaro Patient Information Leaflet is the definitive reference, that figure carries more authority than anything written here.

The full Mounjaro treatment guide covers the six UK strengths and what each stage of titration is designed to do.

Missed doses: the rule your prescriber will give you

Missing a dose occasionally is not a clinical emergency, but the right response depends on exactly how many days have passed since your scheduled injection. As a general principle published in the Mounjaro SmPC: if fewer than four days remain before your next scheduled dose, skip the missed one and resume on your normal day. If more time has elapsed, take it as soon as you remember and then continue on the usual schedule. However, the specifics matter, how many days late you can take a Mounjaro dose is worth reading in full before you decide.

What you should not do is take two injections close together to 'catch up'. Doubling up concentrates the drug and significantly raises the risk of gastrointestinal side effects, including nausea and vomiting severe enough to cause dehydration. According to the NHS guidance on tirzepatide, patients should never take two doses at the same time. If you're regularly struggling to remember your injection day, a phone reminder set the evening before is worth establishing early.

Who controls the dose schedule, and what that means for eligibility

Your prescriber sets the starting dose, confirms each increase, and decides the pace of titration based on how you're tolerating treatment and how your weight is responding. That's a clinical function, not an administrative one. Dose increases at nume (sorry, at our pharmacy) require evidence of the current dose and a clinical review before the next strength is dispensed. No increase is automatic.

The UK licence for Mounjaro covers adults with a BMI of 30 or above, or 27 and above where a weight-related condition is present, more detail on that is at the BMI thresholds for Mounjaro eligibility page. Private treatment means no referral is needed, but the clinical bar is the same. NICE's appraisal of tirzepatide (NICE TA1026) sets the criteria for NHS access; private prescribing follows the licensed indications. If Mounjaro turns out not to be the right fit, alternatives to Mounjaro are worth exploring through a consultation. Check your eligibility with our prescribers if you'd like a same-day clinical review.